Sobre el VHIR
Al Vall d’Hebron Institut de Recerca (VHIR) promovem la recerca biomèdica, la innovació i la docència. Més de 1.800 persones busquen comprendre les malalties avui per millorar-ne el tractament demà.
Recerca
Treballem per entendre les malalties, saber com funcionen i crear millors tractaments per als pacients. Coneix els nostres grups i les seves línies de recerca.
Persones
Les persones són el centre del Vall d'Hebron Institut de Recerca (VHIR). Per això ens vinculem amb els principis de llibertat de recerca, igualtat de gènere i actitud professional que promou l’HRS4R.
Assaigs clínics
La nostra tasca no és només bàsica o translacional; som líders en recerca clínica. Entra per saber quins assaigs clínics estem duent a terme i perquè som referent mundial en aquest camp.
Progrés
Volem que la recerca que es fa al Vall d’Hebron Institut de Recerca (VHIR) sigui un motor de transformació. Com? Identificant noves vies i solucions per fomentar la salut i el benestar de les persones.
Core facilities
Oferim un suport especialitzat als investigadors tant interns com externs, des d’un servei concret fins a l’elaboració d’un projecte complet. Tot, amb una perspectiva de qualitat i agilitat de resposta.
Actualitat
Et donem una porta d’entrada per estar al dia de tot el que passa al Vall d’Hebron Institut de Recerca (VHIR), des de les últimes notícies fins a les activitats i iniciatives solidàries futures que estem organitzant.
Speaker: Prof. Takeaki Ishizawa, M.D., Ph.D., F.A.C.S. - Department of Hepatobiliary-Pancreatic Surgery, Graduate School of Medicine, Osaka Metropolitan University.
Abstract: Intraoperative fluorescence imaging using indocyanine green (ICG) has become used widely for real-time visualization of biological structures and assessment of blood perfusion. I herein demonstrate development history and clinical applications of ICG-fluorescence imaging to HBP surgery. 1) Fluorescence cholangiography: fluorescence images of the extrahepatic bile ducts can be obtained by intrabiliary injection of ICG solution (0.025 mg/mL) or preoperative intravenous injection (IV) of ICG (2.5 mg). The latter technique begins to be used worldwide for confirmation of the bile duct anatomy during minimally-invasive cholecystectomy. 2) Identification of hepatic tumors: IV-injected ICG (0.5 mg/kg) accumulates in hepatocellular carcinoma tissues and in non-cancerous hepatic parenchyma surrounding liver metastasis, which can be used for intraoperative identification of subcapsular hepatic tumors by fluorescence imaging. 3) Hepatic segmentation: ICG solution (0.25 mg in 5 mL indigo-carmine solution) is injected into a tumor-bearing portal branch under ultrasound guidance (positive staining technique). ICG can also be administered intravenously following closure of a corresponding portal pedicle (negative staining technique). These techniques enable long-lasting delineations of segmental boundaries throughout hepatectomy procedures because ICG retains in hepatocytes for more than 5 hours. 4) Assessment of blood perfusion: fluorescence imaging following intraoperative bolus IV ICG (2.5mg) visualizes arterial/portal blood flows and perfusions to the surrounding organs during surgeries with resection/reconstruction of major vessels. Along with current dissemination of ICG-fluorescence imaging, novel target-specific fluorophores and imaging devices are being developed actively. Our approach is to use enzyme-activatable fluorophores for real-time visualization of cancerous tissues and leaking pancreatic juice. The fluorescence imaging techniques will develop into an indispensable intraoperative navigation tool, enhancing safety and curability of HBP surgery.
Host:
Dr. Itxarone Bilbao, Hepatobiliopancreatic surgery and transplants, Children's Hospital and Woman's Hospital.
Dr. Concepción Gómez, Main researcher -Hepato-bilio-pancreatic surgery (HBP) and liver transplantation.
Unirse a la reunión ahora
Id. de reunión: 329 016 051 064
Código de acceso: iWFeVs